Skip to main content
Medical information Clinical review pending

Genetic Testing

TLL1 Gene Atrial Septal Defect Type 6 Genetic Test

This genetic test identifies mutations in the TLL1 gene associated with Atrial Septal Defects (ASDs), a type of congenital heart defect. It uses Next Generation Sequencing (NGS) technology to help understand the genetic basis of the condition.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or Saliva sample. Confirm with the laboratory before booking.
Results
Results are typically available within 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
No special preparation is required for this test. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the TLL1 Gene Atrial Septal Defect Type 6 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a family history of congenital heart defects
  • ✓Patients presenting with symptoms suggestive of ASD
  • ✓Diagnosis confirmation in suspected cases of ASD
  • ✓Genetic counseling for families with ASD history
  • ✓Research purposes related to congenital heart disease
02

In plain language

What this test helps you understand

Identifies mutations in the TLL1 gene linked to Atrial Septal Defects (ASDs), aiding in diagnosis and understanding the genetic basis of the condition. Results can inform personalized management strategies.
The TLL1 Gene Atrial Septal Defect Type 6 NGS Genetic DNA Test is an advanced diagnostic tool designed to identify mutations in the TLL1 gene that are associated with atrial septal defects (ASDs). ASDs are congenital heart defects characterized by an opening in the septum that divides the heart's upper chambers, which can lead to various cardiovascular complications if left untreated. This test employs Next Generation Sequencing (NGS) technology to provide accurate and comprehensive genetic analysis.

This genetic test measures the integrity of the TLL1 gene, identifying potential mutations that could contribute to the development of atrial septal defects. By analyzing the genetic makeup, healthcare providers can better understand the underlying causes of heart defects and tailor treatment strategies accordingly.

Taking the TLL1 Gene Atrial Septal Defect Type 6 NGS Genetic DNA Test offers numerous benefits, including early diagnosis of potential heart defects, informed decision-making regarding treatment options, personalized healthcare management based on genetic insights, and peace of mind for patients and families regarding genetic risks.

After completing the test, results will be available within 3 to 4 weeks. Your healthcare provider will guide you through the results, explaining any identified mutations and their implications for your health and treatment options. It is essential to have a genetic counseling session to discuss the findings and any necessary follow-up actions.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube) or Saliva sample. Confirm with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) is used to analyze the TLL1 gene for specific mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the TLL1 gene. It may not detect mutations in other genes associated with ASDs. A negative result does not completely rule out a genetic cause for ASD. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

An ASD is a hole in the wall (septum) between the two upper chambers of the heart (atria). It is a type of congenital heart defect present at birth.
The TLL1 gene provides instructions for making a protein important for the development of the heart and blood vessels.
This test may be recommended for individuals with a family history of ASDs, those with symptoms, or as part of a broader evaluation for congenital heart disease.
A healthcare provider or genetic counselor will interpret the results, explaining any identified mutations and their potential significance for your health.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
Your doctor will discuss the results with you and recommend appropriate follow-up care or management strategies based on the findings.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp